Dr. Xu Che 车旭
Chief Physician
Department of Pancreatic and Gastric Surgery, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and minimally invasive surgery for pancreatic, hepatobiliary, gastrointestinal, liver metastasis, pancreatic neuroendocrine, and retroperitoneal tumors. Focuses on comprehensive immunotherapy and translational medicine.
Dr. Che holds MD and PhD degrees from Peking Union Medical College. A visiting scholar at Johns Hopkins University School of Medicine in 2016, Dr. Che studied tumor immunotherapy under Elizabeth Jaffee. Research focuses on genetic variations in pancreatic cancer susceptibility and prognosis. Currently serves as Department Director and doctoral supervisor.
Professional roles
- Secretary-General, Pancreatic Disease Branch, China International Exchange and Promotive Association for Medical and Health Care
- Vice Chair, Abdominal Tumor Professional Committee, China Medicine Education Association
- Member, Hepatobiliary and Pancreatic Group, Expert Committee on Enhanced Recovery After Surgery, National Health Commission
- Editorial Board Member, Annals of Pancreatic Cancer
Name order: in Chinese the family name comes first (Che Xu). Papers usually list the name as Xu Che or Che X.
Selected publications
75 papers on PubMed matched by name and affiliation; 27 as first or senior author since 2016. Most recent first- or senior-author papers:
- Eur J Cancer Prev, 2026 (senior author): Association between female reproductive factors and new-onset pancreatic cancer risk: a prospective cohort study. PubMed 40889131
- Pancreatology, 2025 (senior author): Prevalence, clinicopathological features, and prognosis of diabetes in pancreatic cancer: A single-center retrospective cohort study of 1620 patients. PubMed 41274804
- BMC Cancer, 2025 (senior author): Preoperative circulating tumor cells indicate microvascular invasion and dynamical detection indicate the early recurrence of hepatocellular carcinoma. PubMed 40596968
- Crit Rev Oncol Hematol, 2024 (senior author): Spatial transcriptomics in pancreatic cancer: Advances, prospects and challenges. PubMed 38942220
- J Gastroenterol Hepatol, 2024 (senior author): Postoperative adjuvant chemotherapy is important for improving long-term survival in patients with colorectal cancer liver metastases undergoing simultaneous resection. PubMed 38323685
- World J Surg Oncol, 2022 (senior author): Emergency versus delayed hepatectomy following transarterial embolization in spontaneously ruptured hepatocellular carcinoma survivors: a systematic review and meta-analysis. PubMed 36397082
- Front Oncol, 2022 (senior author): Research progress of spontaneous ruptured hepatocellular carcinoma: Systematic review and meta-analysis. PubMed 36249055
- Ann Transl Med, 2022 (senior author): GRSF1 predicts an unfavorable prognosis and promotes tumorigenesis in lung adenocarcinoma based on bioinformatics analysis and in vitro validation. PubMed 35957724
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion